64
Participants
Start Date
November 3, 2017
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2026
Ruxolitinib
"Patients who fulfill eligibility criteria will be entered into the trial to receive Ruxolitinib.~After the screening procedures confirm participation in the research study. The participant will be given a drug diary. The participant will be asked to document information in the drug diary about the study treatment."
Vanderbilt University, Nashville
The Ohio State University, Columbus
Medical College of Wisconsin, Wauwatosa
Washington University, St Louis
Beth Israel Deaconess Medical Center, Boston
Massachusetts General Hospital, Boston
Washington University School of Medicine
OTHER
Vanderbilt University
OTHER
Ohio State University
OTHER
Medical College of Wisconsin
OTHER
Massachusetts General Hospital
OTHER